Jefferies Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.85M | Buy |
21,780
+19,346
| +795% | +$1.72M | 0.02% | 639 |
|
|
2022
Q2 | $202K | Sell |
2,434
-6,316
| -72% | -$503K | ﹤0.01% | 1277 |
|
|
2022
Q1 | $675K | Buy |
8,750
+960
| +12% | +$80.3K | ﹤0.01% | 982 |
|
|
2021
Q4 | $688K | Sell |
7,790
-15,557
| -67% | -$1.28M | ﹤0.01% | 1096 |
|
|
2021
Q3 | $1.8M | Buy |
23,347
+13,121
| +128% | +$1.04M | 0.01% | 787 |
|
|
2021
Q2 | $853K | Buy |
10,226
+3,796
| +59% | +$301K | 0.01% | 1036 |
|
|
2021
Q1 | $486K | Sell |
6,430
-17,663
| -73% | -$1.44M | ﹤0.01% | 1139 |
|
|
2020
Q4 | $2.11M | Buy |
24,093
+23,917
| +13,589% | +$1.9M | 0.02% | 690 |
|
|
2020
Q3 | $13K | Sell |
176
-26,146
| -99% | -$2.65M | ﹤0.01% | 1316 |
|
|
2020
Q2 | $3.25K | Buy |
26,322
+17,889
| +212% | +$1.78M | 0.04% | 390 |
|
|
2020
Q1 | $713K | Sell |
8,433
-56,947
| -87% | -$4.91M | 0.01% | 1168 |
|
|
2019
Q4 | $5.53M | Sell |
65,380
-35,368
| -35% | -$2.67M | 0.04% | 472 |
|
|
2019
Q3 | $6.79M | Buy |
100,748
+82,426
| +450% | +$6.35M | 0.05% | 368 |
|
|
2019
Q2 | $1.57M | Buy |
18,322
+8,855
| +94% | +$758K | 0.01% | 1056 |
|
|
2019
Q1 | $841K | Sell |
9,467
-31,405
| -77% | -$2.91M | 0.01% | 1354 |
|
|
2018
Q4 | $3.48M | Sell |
40,872
-35,260
| -46% | -$3.35M | 0.03% | 564 |
|
|
2018
Q3 | $7.38M | Buy |
76,132
+6,159
| +9% | +$615K | 0.05% | 378 |
|
|
2018
Q2 | $6.59M | Buy |
69,973
+64,909
| +1,282% | +$5.68M | 0.04% | 410 |
|
|
2018
Q1 | $411K | Sell |
5,064
-61,947
| -92% | -$5.32M | ﹤0.01% | 1606 |
|
|
2017
Q4 | $5.97M | Buy |
67,011
+63,988
| +2,117% | +$5.56M | 0.03% | 498 |
|
|
2017
Q3 | $281K | Sell |
3,023
-16,732
| -85% | -$1.48M | ﹤0.01% | 1910 |
|
|
2017
Q2 | $1.79M | Buy |
+19,755
| New | +$1.8M | 0.01% | 982 |
|
|
2017
Q1 | – | Sell |
-7,192
| Closed | -$596K | – | 2330 |
|
|
2016
Q4 | $596K | Buy |
7,192
+1,271
| +21% | +$109K | ﹤0.01% | 1520 |
|
|
2016
Q3 | $548K | Sell |
5,921
-20,073
| -77% | -$1.89M | ﹤0.01% | 1583 |
|
|
2016
Q2 | $2.02M | Sell |
25,994
-5,297
| -17% | -$450K | 0.01% | 856 |
|
|
2016
Q1 | $2.58M | Buy |
31,291
+31,144
| +21,186% | +$2.53M | 0.01% | 735 |
|
|
2015
Q4 | $15K | Sell |
147
-19,447
| -99% | -$2.03M | ﹤0.01% | 2191 |
|
|
2015
Q3 | $2.06M | Sell |
19,594
-12,175
| -38% | -$1.63M | 0.01% | 879 |
|
|
2015
Q2 | $4.34M | Buy |
31,769
+13,114
| +70% | +$1.63M | 0.02% | 576 |
|
|
2015
Q1 | $2.32M | Buy |
18,655
+8,673
| +87% | +$919K | 0.01% | 716 |
|
|
2014
Q4 | $902K | Sell |
9,982
-7,018
| -41% | -$584K | 0.01% | 1022 |
|
|
2014
Q3 | $1.23M | Sell |
17,000
-65,533
| -79% | -$4.31M | 0.01% | 932 |
|
|
2014
Q2 | $5.13M | Sell |
82,533
-8,134
| -9% | -$491K | 0.04% | 348 |
|
|
2014
Q1 | $6.18M | Buy |
90,667
+89,282
| +6,446% | +$6.58M | 0.06% | 253 |
|
|
2013
Q4 | $97K | Sell |
1,385
-17,981
| -93% | -$1.22M | ﹤0.01% | 1704 |
|
|
2013
Q3 | $1.4M | Buy |
19,366
+10,048
| +108% | +$668K | 0.01% | 761 |
|
|
2013
Q2 | $519K | Buy |
+9,318
| New | +$581K | 0.01% | 1046 |
|
Other funds holding BMRN
BBA
Jefferies Group's BMRN Position: Q3 2022 in Review
Jefferies Group increased its BioMarin Pharmaceuticals (BMRN) stake by 795% in Q3 2022, buying an estimated $1.72M and bringing the position to 21,780 shares worth $1.85M. The position accounts for 0.02% of the portfolio, ranked #639.
Jefferies Group first reported a position in BMRN in Q2 2013 and has held it in 37 quarters since. The position peaked at $7.38M in Q3 2018. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.
- Jefferies Group held 21,780 shares of BioMarin Pharmaceuticals worth $1.85M as of Q3 2022.
- Jefferies Group bought 19,346 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1.72M.
- BioMarin Pharmaceuticals made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #639 holding.
- Jefferies Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- Jefferies Group's BioMarin Pharmaceuticals position peaked at $7.38M in Q3 2018.
- 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.